These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 3290992)
1. Apomorphine in the evaluation of dopaminergic function in man. Lal S Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(2-3):117-64. PubMed ID: 3290992 [TBL] [Abstract][Full Text] [Related]
3. Induction of tolerance of dopaminergic responses in man. Lal S; Thavundayil JX; Ng Ying Kin NM; Dai X; Schwartz G; Montoya A J Neural Transm (Vienna); 2008 Aug; 115(8):1189-98. PubMed ID: 18506387 [TBL] [Abstract][Full Text] [Related]
4. Effect of apomorphine, a dopamine receptor agonist, on penile tumescence in normal subjects. Lal S; Ackman D; Thavundayil JX; Kiely ME; Etienne P Prog Neuropsychopharmacol Biol Psychiatry; 1984; 8(4-6):695-9. PubMed ID: 6531440 [TBL] [Abstract][Full Text] [Related]
5. A simple method for the study of yawning in man induced by the dopamine receptor agonist, apomorphine. Lal S; Grassino A; Thavundayil JX; Dubrovsky B Prog Neuropsychopharmacol Biol Psychiatry; 1987; 11(2-3):223-8. PubMed ID: 3628829 [TBL] [Abstract][Full Text] [Related]
7. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia. Meltzer HY; Lee MA; Jayathilake K Neuropsychopharmacology; 2001 Mar; 24(3):278-90. PubMed ID: 11166518 [TBL] [Abstract][Full Text] [Related]
8. Effect of time-of-day on the yawning response to apomorphine in normal subjects. Lal S; Tesfaye Y; Thavundayil JX; Skorzewska A; Schwartz G Neuropsychobiology; 2000; 41(4):178-80. PubMed ID: 10828726 [TBL] [Abstract][Full Text] [Related]
9. Systematic Review of the Apomorphine Challenge Test in the Assessment of Dopaminergic Activity in Schizophrenia. Duval F Healthcare (Basel); 2023 May; 11(10):. PubMed ID: 37239772 [TBL] [Abstract][Full Text] [Related]
10. Apomorphine-induced penile erection and yawning: site of action in brain. Melis MR; Argiolas A; Gessa GL Brain Res; 1987 Jul; 415(1):98-104. PubMed ID: 3497688 [TBL] [Abstract][Full Text] [Related]
14. Hypothalamic-pituitary dopaminergic function in hepatic failure in man. Lal S; Oravec M; Aronoff A; Kiely ME; Guyda H; Solomon S; Nair NP J Neural Transm; 1982; 53(1):7-21. PubMed ID: 7062015 [TBL] [Abstract][Full Text] [Related]
15. Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma? Dépatie L; Lal S J Psychiatry Neurosci; 2001 May; 26(3):203-20. PubMed ID: 11394190 [TBL] [Abstract][Full Text] [Related]
16. The effect of methyltestosterone on the growth hormone response to the dopamine receptor agonist, apomorphine. Lal S; Nair NP; Thavundayil JX; Tawar V; Guyda H; Ayotte C Prog Neuropsychopharmacol Biol Psychiatry; 1991; 15(2):263-8. PubMed ID: 1871327 [TBL] [Abstract][Full Text] [Related]
17. Effects of apomorphine, TL-99 and 3-PPP on yawning in rats. Mogilnicka E; Boissard CG; Delini-Stula A Neuropharmacology; 1984 Jan; 23(1):19-22. PubMed ID: 6144063 [TBL] [Abstract][Full Text] [Related]
18. Dopamine agonists at repeated "autoreceptor-selective" doses: effects upon the sensitivity of A10 dopamine autoreceptors. Jeziorski M; White FJ Synapse; 1989; 4(4):267-80. PubMed ID: 2603146 [TBL] [Abstract][Full Text] [Related]
19. Apomorphine-induced growth hormone response is attenuated by ethanol but not dextromethorphan. Budde H; Zimmermann US; Steffin B; Rommelspacher H; Schmidt LG; Smolka MN Alcohol Clin Exp Res; 2007 Jan; 31(1):100-3. PubMed ID: 17207107 [TBL] [Abstract][Full Text] [Related]